IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
16 Abril 2024 - 3:05PM
IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical
company developing innovative gamma-delta T cell therapies, today
announced that William Ho, CEO and Co-founder, will present at the
Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity
Conference on Thursday, April 18th at 12:30pm ET.
The formal presentation will feature a fireside style Q&A
session with questions welcome from the live virtual
audience. Attendees interested in viewing the live
presentation can register for this event here: Virtual
Healthcare Equity Conference Registration.
The IN8bio management team will also be hosting one-on-one
meetings during the virtual event with registered, qualified
investor attendees. Interested parties should contact their Noble
representative to schedule a meeting.
A video webcast of the presentation will be available following
the event on the Company's website
https://investors.in8bio.com/news-events/events-presentations, and
as part of a complete catalog of presentations available on
Channelchek www.channelchek.com, the investor portal created by
Noble. The webcast will be archived on the company's website and on
Channelchek.com for 90 days following the event.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing
gamma-delta T cell-based immunotherapies for cancer patients.
Gamma-delta T cells are a specialized population of T cells that
possess unique properties, including the ability to differentiate
between healthy and diseased tissue. The company’s lead program,
INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM).
Additional programs include Phase 1 trials in solid and hematologic
tumors, including INB-200 for GBM and INB-100 for patients with
hematologic malignancies undergoing transplantation. For more
information about IN8bio, visit www.IN8bio.com.
About Noble Capital Markets, Inc.
Noble Capital Markets (“Noble”) is a research driven investment
bank that has supported small & microcap companies since 1984.
As a FINRA and SEC licensed broker dealer Noble provides
institutional-quality equity research, merchant and investment
banking, and order execution services. In 2005, Noble established
NobleCon, an investor conference that has grown substantially over
the last decade. Noble launched www.channelchek.com in
2018 - an investor community dedicated exclusively to public small
and micro-cap companies and their industries. Channelchek is the
first service to offer institutional-quality research to the
public, for FREE at every level without a subscription. More than
6,000 public emerging growth companies are listed on the site, with
growing content including research, webcasts, podcasts, and
balanced news.
Corporate Contact:IN8bio, Inc.Glenn Schulman, PharmD,
MPH203.494.7411gdschulman@IN8bio.com
InvestorsMeru AdvisorsLee M. Sternlstern@meruadvisors.com
Media ContactKimberly HaKKH
Advisors917.291.5744kimberly.ha@kkhadvisors.com
IN8bio (NASDAQ:INAB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
IN8bio (NASDAQ:INAB)
Gráfica de Acción Histórica
De May 2023 a May 2024